Modifications of antifungal sensibility testing as suggested by CLSI document M27-A4: proposal for using different culture medium and buffer.
暂无分享,去创建一个
Silviane Bezerra Pinheiro | Hagen Frickmann | Edinaira Sulany Oliveira de Sousa | Ana Cláudia Alves Cortez | Kátia Santana Cruz | Érica Simplício de Souza | Marcia de Souza Carvalho Melhem | João Vicente Braga de Souza | H. Frickmann | M. Melhem | E. S. O. de Sousa | A. C. Cortez | J. V. D. de Souza | K. Cruz
[1] Elizabeth M. Johnson. Issues in antifungal susceptibility testing. , 2008, The Journal of antimicrobial chemotherapy.
[2] S. Córdoba,et al. Evaluation of the in vitro activity of amphotericin B by time-kill curve methodology against large and small capsulate C. neoformans isolates. , 2011, Diagnostic microbiology and infectious disease.
[3] J. Rex,et al. Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B , 1997, Journal of clinical microbiology.
[4] E. Anaissie,et al. Detection of amphotericin B-resistant Candida isolates in a broth-based system , 1995, Antimicrobial agents and chemotherapy.
[5] Ó. Zaragoza. Basic principles of the virulence of Cryptococcus , 2019, Virulence.
[6] M. Cuenca‐Estrella,et al. Influence of Shaking on Antifungal Susceptibility Testing of Cryptococcus neoformans: a Comparison of the NCCLS Standard M27A Medium, Buffered Yeast Nitrogen Base, and RPMI–2% Glucose , 2000, Antimicrobial Agents and Chemotherapy.
[7] M. Pfaller,et al. Multicenter evaluation of four methods of yeast inoculum preparation , 1988, Journal of clinical microbiology.
[8] C. Lass‐Flörl,et al. Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance , 2019, Journal of fungi.
[9] J. Galgiani,et al. Collaborative investigation of variables in susceptibility testing of yeasts , 1990, Antimicrobial Agents and Chemotherapy.
[10] B. Fries,et al. Candidiasis and Mechanisms of Antifungal Resistance , 2020, Antibiotics.
[11] D. Boulware,et al. Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda , 2015, Antimicrobial Agents and Chemotherapy.
[12] H. Badali,et al. Antifungal Resistance Testing and Implications for Management , 2019, Current Fungal Infection Reports.
[13] H. Kamata,et al. Antifungal Susceptibility of Clinical Isolates and Artificially Produced Multi-azole-resistant Strains of Cryptococcus neoformans (formerly: Cryptococcus grubii) to Ravuconazole. , 2020, Medical mycology journal.
[14] E. Mellado,et al. Detection of Resistance to Amphotericin B inCandida Isolates by Using Iso-Sensitest Broth , 2001, Antimicrobial Agents and Chemotherapy.
[15] E. Sionov,et al. Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence , 2009, Antimicrobial Agents and Chemotherapy.
[16] I. Polacheck,et al. Heteroresistance to Fluconazole and Voriconazole inCryptococcus neoformans , 1999, Antimicrobial Agents and Chemotherapy.
[17] J. Rex,et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine , 1995, Journal of clinical microbiology.
[18] R. Standish,et al. First Cryo-Scanning Electron Microscopy Images and X-Ray Microanalyses of Mucoromycotinian Fine Root Endophytes in Vascular Plants , 2020, Frontiers in Microbiology.
[19] T. Kirn,et al. Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results , 2019, Journal of Clinical Microbiology.
[20] A. Fothergill,et al. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance. , 2016, Infectious disease clinics of North America.
[21] B. Clotet. Once-daily dosing of nevirapine in HAART. , 2007, The Journal of antimicrobial chemotherapy.
[22] M. Ghannoum,et al. Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents , 2000, Journal of Clinical Microbiology.
[23] M. Cuenca‐Estrella,et al. Process Analysis of Variables for Standardization of Antifungal Susceptibility Testing of Nonfermentative Yeasts , 2011, Antimicrobial Agents and Chemotherapy.
[24] J. Galgiani,et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests , 1992, Journal of clinical microbiology.
[25] M. Spitzer,et al. Combinatorial strategies for combating invasive fungal infections , 2017, Virulence.
[26] S. Karve,et al. The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection , 2019, Infection and drug resistance.
[27] I. Brukner,et al. A Fundamental Change in Antibiotic Susceptibility Testing Would Better Prevent Therapeutic Failure: From Individual to Population-Based Analysis , 2020, Frontiers in Microbiology.
[28] Impact of Rapid Molecular Diagnostic Testing of Respiratory Viruses on Outcomes of Adults Hospitalized with Respiratory Illness: a Multicenter Quasi-experimental Study , 2018, Journal of Clinical Microbiology.
[29] M. Ghannoum,et al. Susceptibility testing of Cryptococcus neoformans: a microdilution technique , 1992, Journal of clinical microbiology.
[30] H. Frickmann,et al. Factors influencing susceptibility testing of antifungal drugs: a critical review of document M27-A4 from the Clinical and Laboratory Standards Institute (CLSI) , 2020, Brazilian Journal of Microbiology.
[31] J. Galgiani,et al. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts , 1993, Antimicrobial Agents and Chemotherapy.
[32] D. Perlin,et al. Improved Detection of Candida sp. fks Hot Spot Mutants by Using the Method of the CLSI M27-A3 Document with the Addition of Bovine Serum Albumin , 2011, Antimicrobial Agents and Chemotherapy.
[33] M. Arendrup,et al. Echinocandin Susceptibility Testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots , 2011, Antimicrobial Agents and Chemotherapy.
[34] M. Pfaller,et al. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans , 1994, Journal of clinical microbiology.
[35] J. Martínez-Suárez,et al. Improved medium for fluconazole susceptibility testing of Candida albicans , 1994, Antimicrobial Agents and Chemotherapy.
[36] R. Vitale,et al. Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains. , 2012, Journal of medical microbiology.
[37] J. Galgiani,et al. pH and other effects on the antifungal activity of cilofungin (LY121019) , 1989, Antimicrobial Agents and Chemotherapy.
[38] J. Berman,et al. Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence , 2016, mBio.
[39] J. Perfect,et al. Combination Therapy for Invasive Fungal Infections , 2020, Current Fungal Infection Reports.
[40] M. Rinaldi,et al. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard , 1994, Journal of clinical microbiology.
[41] M. Valero,et al. Effect of pH and buffer system on the in-vitro activity of five antifungals against yeasts. , 1997, The Journal of antimicrobial chemotherapy.